Paratek slips into public market with Transcept buy
This article was originally published in Scrip
Executive Summary
Paratek Pharmaceuticals gave up on trying to raise public capital for its Phase III antibiotic on its own in mid-2013, but found a way to list its shares in the US stock market in 2014 via a reverse merger with the flailing specialty pharma company Transcept Pharmaceuticals.